Related Experiment Video

Updated: Apr 18, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K

Novel target to kill CLL

Tadeusz Robak1, Piotr Smolewski1

  • 1MEDICAL UNIVERSITY OF LODZ.

Blood
|January 10, 2015
PubMed

Insights

A new agent, OSU-T315, effectively targets the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. This agent demonstrates significant proapoptotic activity against chronic lymphocytic leukemia (CLL) cells, suggesting therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy.
  • The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway is frequently dysregulated in CLL and plays a critical role in cell survival and proliferation.
  • Targeting key signaling pathways offers a promising therapeutic strategy for CLL.

Purpose of the Study:

  • To investigate the efficacy of OSU-T315, a novel agent targeting the PI3K/AKT pathway.
  • To evaluate the proapoptotic activity of OSU-T315 in chronic lymphocytic leukemia (CLL) cells.
  • To assess the potential therapeutic application of OSU-T315 in CLL treatment.

Main Methods:

  • In vitro studies using CLL cell lines.
  • Treatment with OSU-T315 to assess pathway inhibition.
  • Analysis of apoptosis induction and cell viability.

Main Results:

  • OSU-T315 specifically disrupts the PI3K/AKT signaling pathway.
  • The agent exhibits high proapoptotic activity against CLL cells.
  • Demonstrated significant reduction in cell viability in treated CLL cells.

Conclusions:

  • OSU-T315 is a potent inhibitor of the PI3K/AKT pathway.
  • OSU-T315 shows promising anti-leukemic effects in chronic lymphocytic leukemia.
  • OSU-T315 represents a potential novel therapeutic agent for CLL.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.2K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K